74 related articles for article (PubMed ID: 22042793)
1. MRI detection of breast cancer micrometastases with a fibronectin-targeting contrast agent.
Zhou Z; Qutaish M; Han Z; Schur RM; Liu Y; Wilson DL; Lu ZR
Nat Commun; 2015 Aug; 6():7984. PubMed ID: 26264658
[TBL] [Abstract][Full Text] [Related]
2. Peptide-Conjugated MRI Probe Targeted to Netrin-1, a Novel Metastatic Breast Cancer Biomarker.
Moreau C; Lukačević T; Pallier A; Sobilo J; Aci-Sèche S; Garnier N; Même S; Tóth É; Lacerda S
Bioconjug Chem; 2024 Feb; 35(2):265-275. PubMed ID: 38340041
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance differential analysis for different hormone receptor expression status in HER-2-positive breast cancer.
Zou Z; Huang Y; Zhou Z; Yang Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Jan; 48(1):68-75. PubMed ID: 36935179
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Molecular Imaging with a Single Gd-Based Contrast Agent Reveals Specific Tumor Binding and Retention in Vivo.
Johansen ML; Gao Y; Hutnick MA; Craig SEL; Pokorski JK; Flask CA; Brady-Kalnay SM
Anal Chem; 2017 Jun; 89(11):5932-5939. PubMed ID: 28481080
[TBL] [Abstract][Full Text] [Related]
5. Tumor Detection at 3 Tesla with an Activatable Cell Penetrating Peptide Dendrimer (ACPPD-Gd), a T1 Magnetic Resonance (MR) Molecular Imaging Agent.
Malone CD; Olson ES; Mattrey RF; Jiang T; Tsien RY; Nguyen QT
PLoS One; 2015; 10(9):e0137104. PubMed ID: 26336058
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.
Banerjee SR; Ngen EJ; Rotz MW; Kakkad S; Lisok A; Pracitto R; Pullambhatla M; Chen Z; Shah T; Artemov D; Meade TJ; Bhujwalla ZM; Pomper MG
Angew Chem Int Ed Engl; 2015 Sep; 54(37):10778-82. PubMed ID: 26212031
[TBL] [Abstract][Full Text] [Related]
7. MR - eyes for cancer: looking within an impenetrable disease.
Penet MF; Artemov D; Farahani K; Bhujwalla ZM
NMR Biomed; 2013 Jul; 26(7):745-55. PubMed ID: 23784955
[TBL] [Abstract][Full Text] [Related]
8. Strategies for Target-Specific Contrast Agents for Magnetic Resonance Imaging.
Vithanarachchi SM; Allen MJ
Curr Mol Imaging; 2012 Oct; 1(1):12-25. PubMed ID: 23316452
[TBL] [Abstract][Full Text] [Related]
9. Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status.
Pais A; Degani H
Front Oncol; 2016; 6():100. PubMed ID: 27200289
[TBL] [Abstract][Full Text] [Related]
10. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
11. Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent, genotoxic effects.
Santen R; Cavalieri E; Rogan E; Russo J; Guttenplan J; Ingle J; Yue W
Ann N Y Acad Sci; 2009 Feb; 1155():132-40. PubMed ID: 19250200
[TBL] [Abstract][Full Text] [Related]
12. In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer.
Pais A; Gunanathan C; Margalit R; Biton IE; Yosepovich A; Milstein D; Degani H
Cancer Res; 2011 Dec; 71(24):7387-97. PubMed ID: 22042793
[TBL] [Abstract][Full Text] [Related]
13. Characterization of estrogen-receptor-targeted contrast agents in solution, breast cancer cells, and tumors in vivo.
Pais A; Biton IE; Margalit R; Degani H
Magn Reson Med; 2013 Jul; 70(1):193-206. PubMed ID: 22887470
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
